Drug Information

Drug General Information

Drug ID

D0M9OO

Drug Name

Galinpepimut-S

Indication

Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205]

Phase 3

[1]

Chronic myeloid leukaemia [ICD-11: 2A20; ICD-10: C92.7]

Phase 2

[2]

Malignant pleural mesothelioma [ICD-11: 2C26.0; ICD-9: 163]

Phase 2

[3]

Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163]

Phase 2

[2], [4]

Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0]

Phase 2

[2], [3], [4]

Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183]

Phase 2

[2], [3], [4]

Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1]

Phase 1/2

[3], [4]

Company

Sellas Life Sciences New York, NY

References

REF 1

ClinicalTrials.gov (NCT04229979) GPS Compared With BAT in AML CR2/CR2p. U.S. National Institutes of Health.

REF 2

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 3

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 4

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.